secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001493152-23-012220
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem appoints Ivy Zhang as CFO and Secretary; interim CFO Albert Altro departs
--------------------------------------------------------------------------------

- Albert Altro's interim CFO appointment terminated immediately April 13; Traverse engagement to end by April 30.
- Saundra Pelletier resigned as Secretary but remains CEO; Ivy Zhang appointed CFO and Secretary effective April 13.
- Ivy Zhang receives annual base salary of $410,000, eligible for bonus up to 40% of salary, and standard benefits.
- Zhang previously served as Evofem's Controller (2020-2022) and Director of SEC Reporting; returns from HUYABIO.
- CEO Saundra Pelletier stated goal to achieve quarterly EBITDA breakeven by end of 2023 with Zhang's leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223012220/0001493152-23-012220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223012220/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer